Growth hormone responsiveness: peak stimulated growth hormone levels and other variables in idiopathic short stature (ISS): data from the National Cooperative Growth Study.

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

In children with idiopathic short stature (ISS), growth hormone (GH) response to a provocative test will be inversely related to the first year response to hGH and be a variable accounting for a degree of responsiveness.

Who Took Part

PubMed indexes the participants as children.

How the Study Was Run

The researchers examined the relationship between the peak stimulated GH levels in 3 ISS groups; GH >10 -<25, 25-40, and >40 ng/mL and the first year growth response to rhGH therapy.

Multiple regression analysis with the first year height as the dependent variable and peak stimulated GH was the primary endpoint.

The predictive value of adding each of the other variables was then assessed.

What Was Measured

In children with idiopathic short stature (ISS), growth hormone (GH) response to a provocative test will be inversely related to the first year response to hGH and be a variable accounting for a degree of responsiveness.

The subject headings attached to it are Body Height, Child Development, Growth Disorders, Human Growth Hormone, Population Surveillance, Recombinant Proteins and United States.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Pediatric endocrinology reviews : PER), a journal based in Israel.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.